20,267 results match your criteria lymphoma developed


A Case of Hypophosphatemia due to Oncogenic Osteomalacia in a Patient with Natural Killer T-Cell Lymphoma.

Kidney Blood Press Res 2021 Jul 22:1-5. Epub 2021 Jul 22.

Ochsner Clinical School/The University of Queensland, Brisbane, Queensland, Australia.

Introduction: Oncogenic osteomalacia (Onc-Ost) is a paraneoplastic phenomenon characterized by hypophosphatemia due to elevated fibroblast growth factor-23 (FGF-23). Onc-Ost has been previously reported in patients with germ line mesenchymal tumors and solid organ malignancies. This is the first report of aggressive natural killer (NK) T-cell lymphoma presenting as Onc-Ost. Read More

View Article and Full-Text PDF

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project.

Blood 2021 Jul;138(3):213-220

Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance (CHIMOMO), University of Modena and Reggio Emilia, Modena, Italy.

Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the international prospective T-cell Project (NCT01142674). The primary and secondary end points were 5-year overall survival (OS) and progression-free survival (PFS), respectively. Read More

View Article and Full-Text PDF

CD19/CD22 Dual-Targeted CAR T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: A Safety and Efficacy Study.

Cancer Immunol Res 2021 Jul 21. Epub 2021 Jul 21.

Bone Marrow Transplantation Center, the first Affiliated Hospital, School of Medicine, Zhejiang University

Chimeric antigen receptor (CAR) T-cell therapies that target either CD19 or CD22 alone have potent antilymphoma effects. However, antigen escape-mediated relapse often occurs. CAR T cells targeting both CD19 and CD22 may overcome this limitation. Read More

View Article and Full-Text PDF

Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.

Eur J Haematol 2021 Jul 20. Epub 2021 Jul 20.

Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany.

Objective: To contribute data on long-term outcome and potential curative impact of ASCT in FL, especially following HDT with the BEAM protocol (BCNU, etoposide, cytarabine and melphalan), given very limited data on this topic in the literature.

Patients And Methods: Patients with FL (n=76) were treated in our institution with HDT and ASCT. In the case of long-term remission (≥ 8 years), peripheral blood was tested for minimal residual disease by t(14;18)- and IGH- PCR, including the last follow-up. Read More

View Article and Full-Text PDF

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.

Clin Exp Med 2021 Jul 20. Epub 2021 Jul 20.

Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Avenue, 11528, Athens, Greece.

Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological malignancies is largely unknown. We investigated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with Waldenstrom Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). After the first dose of the vaccine, on D22, WM/CLL/NHL patients had lower NAb titers compared to controls: the median NAb inhibition titer was 17% (range 0-91%, IQR 8-27%) for WM/CLL/NHL patients versus 32% (range 2-98%, IQR 19-48%) for controls (P < 0. Read More

View Article and Full-Text PDF

Evaluation of In Vitro Phototoxicity of a Minibody-IR700 Conjugate Using Cell Monolayer and Multicellular Tumor Spheroid Models.

Cancers (Basel) 2021 Jul 4;13(13). Epub 2021 Jul 4.

Division of Laboratory Medicine, Department of Pathology, Oslo University Hospital-Radiumhospitalet, Ullernchausseen 70, 0379 Oslo, Norway.

Photodynamic therapy (PDT) is a treatment strategy that utilizes photosensitizers (PSs) and light of a specific wavelength to kill cancer cells. However, limited tumor specificity is still a drawback for the clinical application of PDT. To increase the therapeutic efficacy and specificity of PDT, a novel human minibody (MS5) that recognizes a cell surface receptor expressed on various cancer cells was labeled with the hydrophilic phthalocyanine PS IR700 to generate an MS5-IR700 conjugate that is activated by near-infrared (NIR) light. Read More

View Article and Full-Text PDF

Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.

Ann Hematol 2021 Jul 19. Epub 2021 Jul 19.

Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.

Richter's transformation (RT) is a rare complication arising in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and is associated with an overall dismal outcome. The rarity of this entity poses many challenges in understanding its biology and outcomes seen and the optimal treatment approach. We utilized the SEER (Surveillance, Epidemiology and End Results) database to identify patients diagnosed with CLL/SLL between 2000 and 2016 and subsequently had a diagnosis of diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL), thus capturing those who experienced an RT event. Read More

View Article and Full-Text PDF

Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size.

Front Pediatr 2021 1;9:678890. Epub 2021 Jul 1.

Division of Hematology and Tumor, Children's Medical Center, The Second Xiangya Hospital, Central South University, Changsha, China.

This study investigated the management and clinical outcomes along with associated factors of posterior reversible encephalopathy syndrome (PRES) in childhood hematologic/oncologic diseases. We present data from children with hematologic/oncologic diseases who developed PRES after treatment of the primary disease with chemotherapy and hematopoietic stem cell transplantation (HSCT) at 3 medical centers in Changsha, China from 2015 to 2020, and review all previously reported cases with the aim of determining whether this neurologic manifestation affects the disease prognosis. In the clinical cohort of 58 PRES patients, hypertension [pooled odds ratio (OR) = 4. Read More

View Article and Full-Text PDF

Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?

Oncology (Williston Park) 2021 Jul 16;35(7):390-396. Epub 2021 Jul 16.

Department of Internal Medicine, University of Minnesota Medical Center, Minneapolis, MN.

Background: The level of scientific evidence in National Comprehensive Cancer Network (NCCN) guidelines for malignant hematological conditions haven't been recently investigated. We describe the distribution of categories of evidence and consensus (EC) among the 10 most common hematologic malignancies with regard to recommendations for staging, initial and salvage therapy, and surveillance. Methods: We reviewed the level of evidence for the 10 most common hematological malignancies by incidence in the United States as of 2020. Read More

View Article and Full-Text PDF

Paraneoplastic pemphigus associated with rapidly progressing endophthalmitis caused by : A case report.

Eur J Ophthalmol 2021 Jul 16:11206721211033465. Epub 2021 Jul 16.

Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Introduction: The ocular presentation of paraneoplastic pemphigus (PNP) has rarely been reported in the literature. In this report, we describe a 61-year-old male presenting with eruptive skin lesions associated with underlying non-Hodgkin's lymphoma who had rapid progressive corneal perforation with secondary endophthalmitis in the setting of PNP.

Case Description: A 61-year-old male presented to the emergency department complaining of skin eruption mimicking Stevens-Johnson syndrome, which was later found to be related to PNP. Read More

View Article and Full-Text PDF

An update on acalabrutinib to treat chronic lymphocytic leukemia.

Drugs Today (Barc) 2021 Jul;57(7):417-431

Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, California, USA.

Acalabrutinib was approved by the U.S. Food and Drug Administration (FDA) for treatment-naive (TN) and relapsed/refractory (R/R) use for patients with chronic lymphocytic leukemia (CLL) in November 2019 following the phase III ASCEND and ELEVATE-TN registration trials. Read More

View Article and Full-Text PDF

Applications of artificial intelligence in oncologic F-FDG PET/CT imaging: a systematic review.

Ann Transl Med 2021 May;9(9):823

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Artificial intelligence (AI) is a growing field of research that is emerging as a promising adjunct to assist physicians in detection and management of patients with cancer. F-FDG PET imaging helps physicians in detection and management of patients with cancer. In this study we discuss the possible applications of AI in F-FDG PET imaging based on the published studies. Read More

View Article and Full-Text PDF

The use of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography integrated with computed tomography for accurate staging and surveillance in the case of mucosa-associated lymphoid tissue.

J Radiol Case Rep 2021 Mar 31;15(3):19-28. Epub 2021 Mar 31.

Department of Radiation Oncology, University of Minnesota, Minneapolis, USA.

We present the case of a 79-year-old male, who was initially treated for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) of the right eyelid, and later for disease relapse in the stomach. During follow up, he was noted to have developed left arm nodules just medial to the proximal biceps muscle, which were found to be multiply enlarged lymph nodes on subsequent ultrasound imaging. Excisional biopsy of these nodes revealed MALT lymphoma. Read More

View Article and Full-Text PDF

Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.

Blood Cancer J 2021 Jul 15;11(7):130. Epub 2021 Jul 15.

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Despite a characteristic indolent course, a substantial subset of follicular lymphoma (FL) patients has an early relapse with a poor outcome. Cells in the microenvironment may be a key contributor to treatment failure. We used a discovery and validation study design to identify microenvironmental determinants of early failure and then integrated these results into the FLIPI. Read More

View Article and Full-Text PDF

Patient-reported symptom and functioning status during the first 12 months after CAR T-cell therapy for hematological malignancies.

Transplant Cell Ther 2021 Jul 12. Epub 2021 Jul 12.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Background: Chimeric antigen receptor (CAR) T-cell therapy is becoming increasingly used for the treatment of patients with advanced hematological malignancies. However, the symptoms related to the standard of care CAR T-cell therapy during the first year after treatment have not been assessed using patient-reported outcome (PRO) measurements.

Objective: This study aimed to quantify patient's perspectives of symptom burden and functional status using PROs during the first year following CAR-T-cell therapy for hematological malignancies, especially in patients who experienced grade 2-4 toxicities. Read More

View Article and Full-Text PDF

Oncology patients' perception of physicians who use an integrated electronic health record (EHR) during clinic visits: PRIME-EHR double-blind, randomized controlled trial.

Cancer 2021 Jul 15. Epub 2021 Jul 15.

Department of Palliative Care, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Patients with cancer prefer and positively perceive physicians who communicate face-to-face without the use of a computer. However, the use of electronic health records (EHRs) in the examination room remains a practical necessity. On the basis of existing literature, the authors developed and tested an integration model, PRIME-EHR, that focuses on the best-practice guidelines. Read More

View Article and Full-Text PDF

Graft failure after "" T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis.

Leuk Lymphoma 2021 Jul 15:1-8. Epub 2021 Jul 15.

Department of Pediatrics, Hematopoietic Stem Cell Transplantation and Cellular Therapy Unit, Hospital Infantil Universitario "Niño Jesus", Madrid, Spain.

Risk factors and outcomes of GF after TCD haploidentical transplantation in children with hematological malignancies were analyzed. 148 TCD transplants were included. 78 patients were diagnosed of ALL and 70 patients of AML. Read More

View Article and Full-Text PDF

Two unusual cases of autologous HSCT related TMA with kidney injury.

Ann Palliat Med 2021 Jul 8. Epub 2021 Jul 8.

Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing, China.

Kidney injury caused by transplant-associated thrombotic microangiopathy (TA-TMA) in patients who underwent allogeneic hematopoietic stem cell transplantation (allo HSCT) is relatively frequent. However, it is rarely reported in patients undergoing autologous HSCT (aHSCT). There are a few studies reported that TA-TMA could occur in pediatric patients undergoing aHSCT, but the condition in adult patients is rarely described. Read More

View Article and Full-Text PDF

Targeting CD22 for the Treatment of B-Cell Malignancies.

Immunotargets Ther 2021 6;10:225-236. Epub 2021 Jul 6.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Immunotherapeutic agents play an increasingly important role in the treatment of B-cell malignancies. CD19 and CD20 are common targets for lymphoid malignancies, though patients who relapse have few therapeutic options remaining. CD22 is a cell surface sialoglycoprotein uniquely present on B-cells and regulates B-cell function and proliferation. Read More

View Article and Full-Text PDF

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib.

Authors:
Chunzhi Zhang

Front Oncol 2021 28;11:709188. Epub 2021 Jun 28.

Department of Radiation Oncology, Tianjin Hospital, Tianjin, China.

Background: Brain metastasis is the most common form of tumor recurrence after resistance to crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC). The treatment of brain metastasis in patients with ALK-positive NSCLC requires a multidisciplinary approach, including targeted therapy, chemotherapy, and radiotherapy. At present, no optimal treatment for these patients has been identified, although radiotherapy has remained a vital treatment. Read More

View Article and Full-Text PDF

The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma.

Leuk Lymphoma 2021 Jul 14:1-8. Epub 2021 Jul 14.

Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

The study aimed to retrospectively analyze the prognosis of patients with stage IE nasal extranodal natural killer/T-cell lymphoma (ENKTL) with dose reduction to clinical target volume (CTV) by using simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT). Forty-four patients were reviewed retrospectively. The prescribed dose was 45 Gy/25 fractions for extended involved-field site and 50-55 Gy/25 fractions for primary tumor site by using SIB-IMRT. Read More

View Article and Full-Text PDF

Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs.

Cell Rep 2021 Jul;36(2):109372

Metabolism and Cell Signaling Laboratory, Spanish National Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, Madrid 28029, Spain. Electronic address:

B lymphocytes are exquisitely sensitive to fluctuations in nutrient signaling by the Rag GTPases, and 15% of follicular lymphomas (FLs) harbor activating mutations in RRAGC. Hence, a potential therapeutic approach against malignant B cells is to inhibit Rag GTPase signaling, but because such inhibitors are still to be developed, efficacy and safety remain unknown. We generated knockin mice expressing a hypomorphic variant of RagC (Q119L); RagC mice are viable and show attenuated nutrient signaling. Read More

View Article and Full-Text PDF

Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.

Crit Care Med 2021 Jul 2. Epub 2021 Jul 2.

1 Department of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 2 Clinical Pharmacy Specialist in Critical Care, Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 3 Mayo Clinic College of Medicine and Science, Critical Care Clinical Pharmacist, Department of Pharmacy, Mayo Clinic, Rochester, MN. 4 Department of Medicine, Division of Transplantation and Cellular Therapy, University of Miami, Miami, FL. 5 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD. 6 Department of Critical Care, Cleveland Clinic, Cleveland Clinic Lerner School of Medicine, Cleveland, OH. 7 Division of Anesthesiology and Critical Care, Department of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 8 Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY. 9 Roswell Park Comprehensive Cancer Center, Department of Anesthesiology, Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY. 10 Department of Medicine, Division of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN. 11 Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburg, PA. 12 Department of Statistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 13 Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 14 Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD. 15 Department of Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI. 16 Tenure-track Investigator, Surgery Branch of the National Cancer Institute, National Cancer Institute, National Institute of Health, Bethesda, MD. 17 Department of Pulmonary, Critical Care and Sleep Medicine, University of Miami, Miami, FL. 18 Division of Hematology, Division of Experimental Pathology, Mayo Clinic, Rochester, MN. 19 Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO. 20 Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY. 21 Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 22 Department of Medicine, Cleveland Clinic, Cleveland, OH. 23 Transplant and Cellular Therapy Program, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

Objectives: To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.

Design: Retrospective cohort study SETTING:: Nine centers across the U.S. Read More

View Article and Full-Text PDF

A graph convolutional neural network for gene expression data analysis with multiple gene networks.

Stat Med 2021 Jul 14. Epub 2021 Jul 14.

Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.

Spectral graph convolutional neural networks (GCN) are proposed to incorporate important information contained in graphs such as gene networks. In a standard spectral GCN, there is only one gene network to describe the relationships among genes. However, for genomic applications, due to condition- or tissue-specific gene function and regulation, multiple gene networks may be available; it is unclear how to apply GCNs to disease classification with multiple networks. Read More

View Article and Full-Text PDF

Lymphoid Malignancy in Common Variable Immunodeficiency in a Single Center Cohort.

Eur J Haematol 2021 Jul 13. Epub 2021 Jul 13.

Division of Clinical Immunology, Departments of Medicine and Pediatrics, PRISM Immunology Institute, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY, 10029-6574, USA.

One of the complications of common variable immunodeficiency (CVID) is the development of lymphoid malignancy. In this retrospective, single-center study of 647 CVID subjects followed over 4 decades, we present immunologic and clinical phenotypes, pathology, treatment and outcomes of 45 patients (15 males and 30 females, 7%) who developed 49 lymphoid malignancies. The mean age at CVID diagnosis was 42. Read More

View Article and Full-Text PDF

Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia.

Clin Exp Med 2021 Jul 13. Epub 2021 Jul 13.

Department of Internal Medicine, South Carelia Central Hospital, South Carelia Social and Health Care District (Eksote), Lappeenranta, Finland.

The study aim was to determine the benefit of the measurement of serum caspase-cleaved cytokeratin-18 (CK-18) fragment as a prognostic marker of febrile neutropenia (FN) in hematological patients. The study population consisted of 86 consecutive patients with FN who received intensive chemotherapy for hematological malignancy at the adult hematology ward of Kuopio University Hospital. Twenty-three patients (27%) had acute myeloid leukemia, and 63 patients (73%) were autologous stem cell transplant recipients. Read More

View Article and Full-Text PDF

Vertebral MRI-based radiomics model to differentiate multiple myeloma from metastases: influence of features number on logistic regression model performance.

Eur Radiol 2021 Jul 13. Epub 2021 Jul 13.

Department of Radiology, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, People's Republic of China.

Objectives: This study aimed to use the most frequent features to establish a vertebral MRI-based radiomics model that could differentiate multiple myeloma (MM) from metastases and compare the model performance with different features number.

Methods: We retrospectively analyzed conventional MRI (T1WI and fat-suppression T2WI) of 103 MM patients and 138 patients with metastases. The feature selection process included four steps. Read More

View Article and Full-Text PDF

Single Fraction Radiation for Myeloid Sarcoma Is as Effective as Multi-Fraction Regimens for Tumor Regression and Control.

Clin Lymphoma Myeloma Leuk 2021 Jun 13. Epub 2021 Jun 13.

Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Electronic address:

Introduction/background: Myeloid sarcoma is a rare extramedullary manifestation of immature myeloid/monocyte cells. Radiotherapy (RT) yields good local control, but data on different fractionation schemes are limited. The goal of this retrospective study was to share our institutional experience and assess volumetric regression with differential fractionation. Read More

View Article and Full-Text PDF

Progressive Heart Failure and Death as the Initial Manifestation of NK/T-Cell Lymphoma: A Case Report and Literature Review.

Front Cardiovasc Med 2021 24;8:685736. Epub 2021 Jun 24.

Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.

Natural killer/T-cell (NK/T-cell) lymphoma is a rare-type non-Hodgkin lymphoma derived from NK cells or cytotoxic T cells. Here, we present a case of a 40-year-old woman who experienced quick-developed global heart failure and then was diagnosed with NK/T-cell lymphoma through lymphoid biopsy. Neither transthoracic echocardiography nor any radiological images detected a mass in her heart or pericardium. Read More

View Article and Full-Text PDF

Development and Evaluation of a Leukemia Diagnosis System Using Deep Learning in Real Clinical Scenarios.

Front Pediatr 2021 24;9:693676. Epub 2021 Jun 24.

Pediatric AI Clinical Application and Research Center, Shanghai Children's Medical Center, Shanghai, China.

Leukemia is the most common malignancy affecting children. The morphologic analysis of bone marrow smears is an important initial step for diagnosis. Recent publications demonstrated that artificial intelligence is able to classify blood cells but a long way from clinical use. Read More

View Article and Full-Text PDF